Janice Bailey, Jason Acker and Louise St-Onge have joined the GlycoNet Board of Directors
Category: Network News
GlycoNet researchers have developed specialized nanobodies that could enable the immune system to fight triple-negative breast cancer more effectively.
Congratulations to Drs. Carolyn Bertozzi and Morten Meldal whose groundbreaking work has opened doors in glycomics innovation.
Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Read some highlights from the 2022 Canadian Glycomics Symposium.
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.